Literature DB >> 15710817

Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.

Ai Uemura1, Makoto Nakamura, Shu Kachi, Yuji Nishizawa, Tetsu Asami, Yozo Miyake, Hiroko Terasaki.   

Abstract

OBJECTIVE: To determine whether plasmin will cleave the laminin and fibronectin located at the vitreoretinal junction during plasmin-assisted vitrectomy.
METHODS: Western blot analyses were performed with antilaminin or anti-fibronectin antibodies on the internal limiting membranes collected from patients with macular holes or cystoid macular edema who underwent vitrectomy with or without plasmin. The results were compared with the results of in vitro experiments in which commercially available laminin and fibronectin were exposed to commercially available plasmin.
RESULTS: In all eyes treated with plasmin, a posterior vitreous detachment was not present before surgery but was created easily with a minimal suction of less than 100 mm Hg during vitrectomy. Western blot analyses showed that the laminin and fibronectin in the internal limiting membrane exposed to plasmin during vitrectomy were degraded to several fragments of lower molecular weights, including a fragment of approximately 13,000 Da for laminin and a fragment of approximately 30,000 Da for fibronectin. These lower-molecular-weight fragments also appeared in the in vitro experiments.
CONCLUSION: The laminin and fibronectin at the vitreoretinal junction are degraded during plasmin-assisted vitrectomy. CLINICAL RELEVANCE: These findings provide evidence for the efficacy of using plasmin to create a posterior vitreous detachment during vitreoretinal surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710817     DOI: 10.1001/archopht.123.2.209

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  11 in total

1.  Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.

Authors:  M G Martínez-Hernández; L A Baiza-Gutman; A Castillo-Trápala; D Randall Armant
Journal:  Reproduction       Date:  2010-11-12       Impact factor: 3.906

2.  Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.

Authors:  David T Goldenberg; Frank J Giblin; Mei Cheng; Shravan K Chintala; Michael T Trese; Kimberly A Drenser; Alan J Ruby
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

3.  Ocriplasmin for treatment of stage 2 macular holes: early clinical results.

Authors:  John B Miller; Leo A Kim; David M Wu; Demetrios G Vavvas; Dean Eliott; Deeba Husain
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Jul-Aug       Impact factor: 1.300

4.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review.

Authors:  Eric W Schneider; Mark W Johnson
Journal:  Clin Ophthalmol       Date:  2011-08-18

5.  Pharmacologic vitreolysis.

Authors:  Hossein Nazari; Mehdi Modarres-Zadeh; Arash Maleki
Journal:  J Ophthalmic Vis Res       Date:  2010-01

Review 6.  Surgical management of diabetic retinopathy.

Authors:  Vishali Gupta; J Fernando Arevalo
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Oct-Dec

Review 7.  Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion.

Authors:  Francisco R Stefanini; Maurício Maia; Paulo Falabella; Marcel Pfister; Moritz Niemeyer; Amir H Kashani; Mark S Humayun; Michael J Koss
Journal:  Clin Ophthalmol       Date:  2014-05-06

8.  High osmolarity effect of intravitreal plasmin enzyme on rabbit retina.

Authors:  Tetsu Asami; Shu Kachi; Usama Ali Mohamed; Yasuki Ito; Hiroko Terasaki
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

9.  Surgical management in advanced stages of retinopathy of prematurity; our experience.

Authors:  Ramak Roohipoor; Reza Karkhaneh; Mohammad Riazi-Esfahani; Fariba Ghasemi; Mehdi Nili-Ahmadabadi
Journal:  J Ophthalmic Vis Res       Date:  2009-07

Review 10.  Ocriplasmin for vitreoretinal diseases.

Authors:  Irena Tsui; Carolyn K Pan; Ehsan Rahimy; Steven D Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.